Metastatic Medullary Thyroid Cancer
Conditions
Keywords
Medullary Thyroid Cancer (MTC) vandetanib caprelsa
Brief summary
In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib). The characteristics of patients receiving Caprelsa® (vandetanib) will be described. Therefore real life data regarding demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with Caprelsa® (vandetanib) and time of progression or death (if applicable) will be included.
Interventions
DRUGCaprelsa
Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
Sponsors
Genzyme, a Sanofi Company
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The subject population that will be observed in this registry, must fulfil all of the following criteria: 1. Provision of subject Informed Consent 2. Patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic MTC 3. Patients who already received a prescription for vandetanib in accordance with the scientific leaflet and fulfilling the reimbursement criteria of vandetanib and who are currently treated or have been treated with vandetanib 100 mg or 300 mg tablets. The prescription of the medicinal product is clearly separated from the decision to include the subject in the registry.
Exclusion criteria
Not applicable since patients participating in another study can take part in this registry.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary objective of this registry is to describe the characteristics of patients who receive Caprelsa® and who are fulfilling the reimbursement criteria. | Up to 16 months | In this registry the following real life data will be collected: demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with vandetanib and time of progression or death (if applicable). |
Countries
Belgium
Outcome results
None listed